Nelson Barrientos U., Raúl Juliet P., Alan Rapoport, Philipe Salles G, Anna Milán S., Paulina Meza C.
{"title":"Cefalea por abuso de medicamentos y sus marcadores clínicos","authors":"Nelson Barrientos U., Raúl Juliet P., Alan Rapoport, Philipe Salles G, Anna Milán S., Paulina Meza C.","doi":"10.4067/s0717-92272022000100026","DOIUrl":null,"url":null,"abstract":"Introduction: Clinical markers of medication overuse headache (MOH) are based on headache classification developed by the International Headache Society (IHS). This classification include only two criteria: frequency of headache days must be 15 or more days per month for at least three or more months; and the number of days of overuse medication must be either 10 or 15 days per month depending on the type of medication. However, patients often have others distinct associated clinical markers, which are overlooked by most physicians during the initial evaluation. Methodology: This study is a prospective, longitudinal and observational study of 76 patients admitted to DIPRECA ́s hospital Headache Unit. They were all diagnosed with, MOH according to the criteria established by the his ICHD III beta.(1) Patients were given standard treatment including detoxification and preventive medications and followed for 6 months. Symptoms of interest were recorded in at each clinical monitoring visit and assessment scales such as Zung, MIDAS, HIT-6 were administered. Results: Overused medications included nonsteroidal anti-inflammatory drugs (NSAIDs), triptans and ergots. The most significant clinical symptoms associated were: awaking in the morning with headache, awaking the patient at dawn by headache, attention difficulties, depression, cervical pain and myofascial pain syndrome. All symptoms significantly improved when treatment began, as did quality of life as measured by MIDAS and HIT-6 scales. Discussion: In evaluating patients with MOH consider both the ICHD III beta diagnostic criteria and the common and specific symptoms seen in most cases of MOH.","PeriodicalId":39300,"journal":{"name":"Revista Chilena de Neuro-Psiquiatria","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Chilena de Neuro-Psiquiatria","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4067/s0717-92272022000100026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Clinical markers of medication overuse headache (MOH) are based on headache classification developed by the International Headache Society (IHS). This classification include only two criteria: frequency of headache days must be 15 or more days per month for at least three or more months; and the number of days of overuse medication must be either 10 or 15 days per month depending on the type of medication. However, patients often have others distinct associated clinical markers, which are overlooked by most physicians during the initial evaluation. Methodology: This study is a prospective, longitudinal and observational study of 76 patients admitted to DIPRECA ́s hospital Headache Unit. They were all diagnosed with, MOH according to the criteria established by the his ICHD III beta.(1) Patients were given standard treatment including detoxification and preventive medications and followed for 6 months. Symptoms of interest were recorded in at each clinical monitoring visit and assessment scales such as Zung, MIDAS, HIT-6 were administered. Results: Overused medications included nonsteroidal anti-inflammatory drugs (NSAIDs), triptans and ergots. The most significant clinical symptoms associated were: awaking in the morning with headache, awaking the patient at dawn by headache, attention difficulties, depression, cervical pain and myofascial pain syndrome. All symptoms significantly improved when treatment began, as did quality of life as measured by MIDAS and HIT-6 scales. Discussion: In evaluating patients with MOH consider both the ICHD III beta diagnostic criteria and the common and specific symptoms seen in most cases of MOH.
药物过度使用性头痛(MOH)的临床标志是基于国际头痛学会(IHS)制定的头痛分类。该分类仅包括两个标准:头痛天数的频率必须为每月15天或以上,至少持续3个月或以上;过度使用药物的天数必须是每月10天或15天,这取决于药物的类型。然而,患者通常还有其他明显的相关临床标志,这些标志在最初的评估中被大多数医生所忽视。方法:本研究是一项前瞻性、纵向和观察性研究,纳入了DIPRECA医院头痛科收治的76例患者。(1)给予包括排毒和预防性药物在内的标准治疗,随访6个月。在每次临床监测访问时记录感兴趣的症状,并使用Zung, MIDAS, HIT-6等评估量表。结果:过度使用的药物包括非甾体抗炎药(NSAIDs)、曲坦类药物和麦角糖。最显著的临床症状为:早晨醒来头痛、黎明醒来头痛、注意力困难、抑郁、颈痛和肌筋膜疼痛综合征。治疗开始后,所有症状均显著改善,MIDAS和HIT-6量表测量的生活质量也有所改善。讨论:在评估MOH患者时,既要考虑ICHD III β诊断标准,也要考虑在大多数MOH病例中出现的常见和特定症状。
期刊介绍:
La Revista Chilena de Neuro-psychiatry was established in 1947 and belongs to the Society of Neurology, Neurosurgery and Psychiatry, Chile (SONEPSYN), of which his body of scientific expression. The financial management of the magazine conducted the directory SONEPSYN. The editorial management is delegated to an editor and editorial committee, who have full freedom and independence in this area. Is a quarterly publication. The journal publishes original articles and unpublished covering basic and clinical aspects of the three specialties with ethics, medical education, physician-patient relationship, care management, public health, epidemiology, sociology and medical profession.